PPG introduces PPG ONE RANGE portfolio for onboard maintenance PPG announced the launch of the PPG ONE RANGE™ portfolio of five one-component marine coatings at the SMM 2026 maritime industry trade fair in Hamburg, Germany. Designed to simplify onboard fleet…
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer Agenus , a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase…
Komodo Health and NCQA Collaborate to Accelerate the Future of Healthcare Quality Measurement Komodo Health®, an AI-powered healthcare intelligence company, announced a multi-year strategic effort with the National Committee for Quality Assurance (NCQA) to modernize how healthcare quality measures are…
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China Summit Therapeutics Inc. noted that its partner Akeso Inc. announced positive topline…
Maxis AI Introduces the First Verticalized Context Layer for Life Sciences, a Governed Execution Fabric That Makes Enterprise AI Reliable, Cost-Efficient, and Regulatory Compliant Maxis AI introduced MaxisAI Holarchy, its Verticalized Context Layer, a governed institutional memory that gives life sciences…
Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. announced the continued participation of the University of Georgia’s Student Industry Fellows Program in the ai²…
Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City Cardio Diagnostics Holdings, Inc. an AI-driven precision cardiovascular medicine company, announced the official launch of its in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa.…
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a…
Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology based in Barcelona, announced a collaboration and licensing agreement with Shenzhen CrystalO…
Greenstone Biosciences Receives NIH R61 Grant to Advance Cardiac Fibrosis Therapeutics for Duchenne Muscular Dystrophy Greenstone Biosciences, a biotechnology company advancing New Approach Methodologies (NAMs) for drug discovery, announced that it has received a Catalyze R61 award from the National…
New Multi-Center Study Shows equicenta® CTM, Ready-to-Use, Equine Umbilical Cord Allograft Outperforms Standard of Care in Returning Performance Horses to Work Equine Performance Labs (EPL), the team behind equicenta® CTM — announced the publication of a peer-reviewed, prospective, controlled clinical…
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the…